Antidepressants: gradual and accompanied withdrawal avoids relapse risk

Many patients hesitate to stop antidepressants due to fears of withdrawal syndrome or symptom relapse. A study published in The Lancet shows that a gradual withdrawal, combined with psychological support, does not increase relapse risk compared to continuing the treatment.

Stopping antidepressants often poses a major challenge for patients with depressive or anxiety disorders. Many extend their treatment for years, fearing the return of symptoms or the effects of poorly managed withdrawal. A recent study, conducted by French experts and published on December 11, 2025, in The Lancet, provides reassuring insights on this issue.

The research compares two approaches: continuing the treatment and a gradual withdrawal accompanied by psychological support. The findings show that both methods are equally safe, with similar relapse risks. They are far preferable to an abrupt interruption or rapid dose reduction, which heighten complications.

Florian Naudet, professor at the University of Rennes and lead author of the study, states: “These two strategies – cautious withdrawal and continuing the treatment – are both safer than an abrupt interruption and a rapid reduction of antidepressants. Patients who are considering it should know that it is possible to stop, provided it is done within a shared decision with their doctor and with proper support.”

This publication highlights the importance of a shared decision between patient and physician, along with tailored support. It may encourage more individuals to consider a controlled withdrawal, while avoiding the pitfalls of a hasty cessation. The researchers emphasize the need for personalized follow-up to minimize risks associated with long-term treatments.

Related Articles

UCLA study illustration: Patient receiving accelerated TMS therapy in clinic, with efficacy graphs comparing 5-day vs 6-week treatments.
Image generated by AI

UCLA study finds five-day accelerated TMS schedule performed similarly to conventional six-week course for treatment-resistant depression

Reported by AI Image generated by AI Fact checked

Researchers at UCLA Health report that delivering transcranial magnetic stimulation (TMS) in an intensive five-day schedule—five sessions per day for five days—was associated with depression symptom improvements comparable to a conventional six-week schedule in a retrospective analysis of 175 patients with treatment-resistant depression. The study also found that some patients who showed little immediate change after the accelerated course improved noticeably in the following weeks.

Health and Human Services Secretary Robert F. Kennedy Jr. unveiled a federal initiative that he says is intended to curb what the department describes as inappropriate prescribing of psychiatric medications — including widely used antidepressants such as Prozac and Zoloft — while expanding access to nonmedication treatments like psychotherapy and family support services. Mental health groups and psychiatrists said some elements, including better training and safer tapering support, could be helpful, but criticized Kennedy’s framing as too simplistic.

Reported by AI

A small clinical trial has found that a single dose of the psychedelic drug dimethyltryptamine (DMT) led to rapid and sustained reductions in depression symptoms when combined with therapy. Participants experienced improvements lasting up to six months, with mild side effects reported. The study highlights potential benefits of short-acting psychedelics for treatment-resistant depression.

A large review of randomized trials indicates that statins do not cause the majority of side effects listed on their labels. Symptoms such as memory problems and depression occurred at similar rates in statin users and those taking placebos. The findings aim to address concerns that have led some patients to avoid these heart-protecting medications.

Reported by AI Fact checked

Fathers in Sweden were less likely to receive new psychiatric diagnoses during their partner’s pregnancy and in the first months after birth, but diagnoses of depression and stress-related disorders rose by more than 30% toward the end of the child’s first year, according to a large national register study published in JAMA Network Open.

A placebo-controlled trial has shown that a single dose of psilocybin, the active ingredient in magic mushrooms, leads to rapid and lasting reductions in obsessive-compulsive disorder symptoms among treatment-resistant patients. The effects persisted for at least 12 weeks in participants who had not responded to conventional therapies. Researchers highlight the potential of this psychedelic for mental health treatment, though larger studies are needed.

Reported by AI

A new study shows that slowing breathing rates can reduce anxiety-like behaviors even without any conscious effort or belief in its effects. Researchers used mice to demonstrate that the benefits come from physiological changes rather than placebo. The findings were presented at a summit in Los Angeles earlier this month.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline